A robust approach to differentiate human monocyte-derived microglia from peripheral blood mononuclear cells

Hazel Quek; Carla Cuní-López; Romal Stewart; Yi Chieh Lim; Tara L. Roberts; Anthony R. White

doi:10.1016/j.xpro.2022.101747

A robust approach to differentiate human monocyte-derived microglia from peripheral blood mononuclear cells

Hazel Quek, Carla Cuní-López, Romal Stewart, Yi Chieh Lim, Tara L. Roberts, Anthony R. White

Western Sydney University

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Microglia are implicated in most neurodegenerative diseases. Here, we present a robust and efficient protocol to differentiate monocyte-derived microglia-like cells (MDMi) from whole blood. The protocol consists of three parts. The first part will describe two methods for PBMC isolation. This will be followed by MDMi differentiation, and lastly, the characterization of MDMi by immunocytochemistry. MDMi can be used to investigate microglial-related responses in various age-related neurodegenerative diseases and can be applied to drug testing on a personalized basis. For complete details on the use and execution of this protocol, please refer to Quek et al. (2022).

Original language	English
Article number	101747
Number of pages	14
Journal	Star Protocols
Volume	3
Issue number	4
DOIs	https://doi.org/10.1016/j.xpro.2022.101747
Publication status	Published - 16 Dec 2022

Bibliographical note

Publisher Copyright:
© 2022 The Author(s)

Open Access - Access Right Statement

Access to Document

10.1016/j.xpro.2022.101747

Cite this

@article{ba9949b41ca14971bf838d4ffac8f407,

title = "A robust approach to differentiate human monocyte-derived microglia from peripheral blood mononuclear cells",

abstract = "Microglia are implicated in most neurodegenerative diseases. Here, we present a robust and efficient protocol to differentiate monocyte-derived microglia-like cells (MDMi) from whole blood. The protocol consists of three parts. The first part will describe two methods for PBMC isolation. This will be followed by MDMi differentiation, and lastly, the characterization of MDMi by immunocytochemistry. MDMi can be used to investigate microglial-related responses in various age-related neurodegenerative diseases and can be applied to drug testing on a personalized basis. For complete details on the use and execution of this protocol, please refer to Quek et al. (2022).",

author = "Hazel Quek and Carla Cun{\'i}-L{\'o}pez and Romal Stewart and Lim, {Yi Chieh} and Roberts, {Tara L.} and White, {Anthony R.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = dec,

day = "16",

doi = "10.1016/j.xpro.2022.101747",

language = "English",

volume = "3",

journal = "Star Protocols",

issn = "2666-1667",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - A robust approach to differentiate human monocyte-derived microglia from peripheral blood mononuclear cells

AU - Quek, Hazel

AU - Cuní-López, Carla

AU - Stewart, Romal

AU - Lim, Yi Chieh

AU - Roberts, Tara L.

AU - White, Anthony R.

PY - 2022/12/16

Y1 - 2022/12/16

N2 - Microglia are implicated in most neurodegenerative diseases. Here, we present a robust and efficient protocol to differentiate monocyte-derived microglia-like cells (MDMi) from whole blood. The protocol consists of three parts. The first part will describe two methods for PBMC isolation. This will be followed by MDMi differentiation, and lastly, the characterization of MDMi by immunocytochemistry. MDMi can be used to investigate microglial-related responses in various age-related neurodegenerative diseases and can be applied to drug testing on a personalized basis. For complete details on the use and execution of this protocol, please refer to Quek et al. (2022).

AB - Microglia are implicated in most neurodegenerative diseases. Here, we present a robust and efficient protocol to differentiate monocyte-derived microglia-like cells (MDMi) from whole blood. The protocol consists of three parts. The first part will describe two methods for PBMC isolation. This will be followed by MDMi differentiation, and lastly, the characterization of MDMi by immunocytochemistry. MDMi can be used to investigate microglial-related responses in various age-related neurodegenerative diseases and can be applied to drug testing on a personalized basis. For complete details on the use and execution of this protocol, please refer to Quek et al. (2022).

UR - https://hdl.handle.net/1959.7/uws:68058

U2 - 10.1016/j.xpro.2022.101747

DO - 10.1016/j.xpro.2022.101747

M3 - Article

SN - 2666-1667

VL - 3

JO - Star Protocols

JF - Star Protocols

IS - 4

M1 - 101747

ER -

A robust approach to differentiate human monocyte-derived microglia from peripheral blood mononuclear cells

Abstract

Bibliographical note

Open Access - Access Right Statement

Access to Document

Other files and links

Fingerprint

Cite this